Acadia Pharmaceuticals Inc
ACAD· Nasdaq
ACADAcadia Pharmaceuticals Inc
Released May 8, 2024, after the close
10-Q filed May 9, 2024, 39 days after period end · 0000950170-24-056077
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $205.83M | $118.46M | $115.47M | $106.55M |
| Net Income | $16.56M | -$43.02M | -$113.06M | -$66.45M |
| EPS Diluted |
Acadia Pharmaceuticals Inc · CIK 1070494 · Engraved from SEC EDGAR
| $0.10 |
| -$0.27 |
| -$0.70 |
| -$0.42 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
